These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

675 related items for PubMed ID: 18762226

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immunogenicity of sanofi pasteur tetravalent dengue vaccine.
    Guy B.
    J Clin Virol; 2009 Oct; 46 Suppl 2():S16-9. PubMed ID: 19800561
    [Abstract] [Full Text] [Related]

  • 3. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4.
    Deauvieau F, Sanchez V, Balas C, Kennel A, DE Montfort A, Lang J, Guy B.
    Am J Trop Med Hyg; 2007 Jan; 76(1):144-54. PubMed ID: 17255244
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice.
    van der Most RG, Harrington LE, Giuggio V, Mahar PL, Ahmed R.
    Virology; 2002 Apr 25; 296(1):117-24. PubMed ID: 12036323
    [Abstract] [Full Text] [Related]

  • 10. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH, Galán-Herrera JF, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, Guy B, Lang J.
    Hum Vaccin Immunother; 2014 Apr 25; 10(10):2853-63. PubMed ID: 25483647
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
    Lanata CF, Andrade T, Gil AI, Terrones C, Valladolid O, Zambrano B, Saville M, Crevat D.
    Vaccine; 2012 Sep 07; 30(41):5935-41. PubMed ID: 22863660
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.
    Koraka P, Benton S, van Amerongen G, Stittelaar KJ, Osterhaus AD.
    Vaccine; 2007 Jul 20; 25(29):5409-16. PubMed ID: 17560694
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate.
    Chu H, George SL, Stinchcomb DT, Osorio JE, Partidos CD.
    J Infect Dis; 2015 Nov 15; 212(10):1618-28. PubMed ID: 25943203
    [Abstract] [Full Text] [Related]

  • 17. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.
    Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J.
    J Infect Dis; 2010 Feb 01; 201(3):370-7. PubMed ID: 20059357
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.